Search

Search Constraints

You searched for: Author/Creator Han, J.-Y.

Search Results

1. Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial. (January 2020)